Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer (RAD)
A Phase II Study to Evaluate the Efficacy and Tolerability of Ramosetron, Aprepitant and Dexamethasone (RAD) in Preventing Cisplatin-induced Nausea and Vomiting in Chemotherapy-naïve Patients With Solid Cancer
Sponsor: Hallym University Medical Center
A PHASE2 clinical study on Postoperative Nausea and Vomiting and Solid Tumour, this trial is ongoing. The trial is conducted by Hallym University Medical Center and has accumulated 7 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hallym University Medical Center
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .